大鼠缰核与下丘脑外侧区在调节心血管活动方面的机能联系

电刺激大鼠下丘脑外侧区（LH）,动脉压明显升高,心率加快,在刺激电极同侧缰核（Hb)内微量注射盐酸利多卡因、电刺激LH引起的升压反应可被阻断38.9%,心率增快反应可被阻断44.4%,双侧Hb内微量注射盐酸利多卡因,电刺激LH引起的升压反应可被阻断40.7%,心率增快反应可被阻断41.2% ,单侧或双侧Hb内微量注射人工脑脊液均不能阻断电刺激LH引起的心血管反应。电刺激大鼠Hb,动脉压明显升高,心率无明显改变,在刺激电极同侧LH内微量注射盐酸利多卡因,电刺激Hb引起的升压反应可被阻断63.2%,双侧LH内微量注射盐酸利多卡因,电刺激Hb引起的升压反应可被阻断62.6%,单侧或双侧LH内微量注射人工脑脊液均不能阻断电刺激Hb引起的心血管反应。本实验提示Hb与LH在调节心血管活动方面有协同作用。     

神经肽Y和去甲肾上腺素在杏仁内侧核内影响血压和心率中…

分别向杏仁内侧核（ＭＡＮ）内微量注射去甲肾上腺素（ＮＡ）或神经肽Ｙ（ＮＰＹ）。ＮＡ引起血压长高,心率加快;而ＮＰＹ引起血压降低,心率减慢。如果注入不能改变血压的小剂量ＮＰＹ,则可抑制ＮＡ引起的升压作用,反映ＮＰＹ与ＮＡ共同参与心血管活动的中枢性调节过程。向ＭＡＮ中注射ＮＰＹ后血中ＮＡ的含量也相应降低,表明在ＭＡＮ中注射ＮＰＹ引起的血压、心率反应是通过降低血浆中ＮＡ含量而实现的。     

神经肽Y和去甲肾上腺素在杏仁内侧核内影响血压和心率中的相互作用

分别向杏仁内侧核（ＭＡＮ）内微量注射去甲肾上腺素（ＮＡ）或神经肽Ｙ（ＮＰＹ）。ＮＡ引起血压升高,心率加快;而ＮＰＹ引起血压降低,心率减慢。如果注入不能改变血压的小剂量ＮＰＹ,则可抑制ＮＡ引起的升压作用,反映ＮＰＹ与ＮＡ共同参与心血管活动的中枢性调节过程。向ＭＡＮ中注射ＮＰＹ后血中ＮＡ的含量也相应降低,表明在ＭＡＮ中注射ＮＰＹ引起的血压、心率反应是通过降低血浆中ＮＡ含量而实现的。     

迷走神经兴奋对HRV的影响及其机制的初步分析

实验在氯醛糖加氨基甲酸乙酯麻醉的新西兰兔上进行。记录血压、心率、心电图和心率变异性（ＨＲＶ）频谱分析。电刺激减压神经（ＤＮ）,疑核（ＮＡ）和右侧迷走神经（ＲＶ）外周端,均引起心率和血压下降（Ｐ＜０．００１）,总变异性（ＴＶ）、低频成分（ＬＦ）、高频成分（ＨＦ）、ＬＦ／ＨＦ比值（ＬＦ／ＨＦ）和极低频成分（ＶＬＦ）增大（Ｐ＜０．０５－０．００１）。静脉注射阿托品可使上述反应显著减小（Ｐ＜０．０５－０．０１）,而静脉注射心得安仅可阻断ＤＮ和ＮＡ所致ＬＦ的增大（Ｐ＜０．０５）。以上结果表明：迷走神经是ＨＲＶ的主要调节者之一;ＨＦ由迷走神经单独介导;ＬＦ受迷走神经和交感神经共同调制;迷走神经参与ＶＬＦ波的形成     

迷走传入的投射区在电刺激颈迷走神经中枢端引起的降压反应中的作用

文献报道迷走传入直接或间接投射至多个脑区。本工作分别检验这些脑区在迷走传入引起的降压、降心率反应中的作用。在乌拉坦麻醉、双侧切断颈迷走神经的大鼠,将普鲁卡因微量注入孤束核或β-内啡肽抗血清注入延髓头端腹外侧区(RVL)均可明显减小电刺激预迷走神经中枢端引起的降压(DpV)和降心率反应,但分别将心得安、β-内啡肽抗血清注入室旁核或普鲁卡因注入最后区对DpV和心率减慢反应均无明显影响。保留右侧颈迷走神经的大鼠,在甲基阿托品(i.v.)阻断心迷走神经作用后DpV亦无明显变化,但心率减慢反应被衰减。鉴于我们以往的实验显示孤束核可通过其β-内啡肽能投射纤维作用于RVL而起降压作用,以上结果提示:迷走传入通过孤束核的β-内啡肽能神经元对RVL-交感兴奋神经元起抑制作用是引起降压反应的机制之一。     

下丘脑穹窿周围区不同部位兴奋对心肌Po_2及ECG－ST的影响

电刺激下丘脑穹窿周围区（ＰＦＡ）的下丘脑背内侧核（ＤＭＨ）,下丘脑腹内侧核（ＶＭＨ）与下丘脑外侧区（ＬＨＡ）均可引起心肌Ｐ０＿２下降与血压升高,而以ＤＭＨ所致的心肌Ｐ０,下降最明显（Ｐ＜０．０１）。心得安可取消电刺激ＬＨＡ所致的心肌ＰＯ＿２下降,部分取消电刺激ＶＭＨ引起的心肌ＰＯ＿２下降,而不改变电刺激ＤＭＨ所致的心肌ＰＯ＿２下降（Ｐ＞０．０５）。ＤＭＨ、ＶＭＨ微量注射谷氨酸钠（０．１ｍｏｌ／Ｌ０．５μｌ）均可诱发升压反应和ＥＣＧ－ＳＴ压低,而ＬＨＡ微量注射谷氨酸却导致降压反应,对ＥＣＧ－ＳＴ无明显影响。上述结果提示ＤＭＨ为ＰＦＡ各区诱发心肌缺血缺氧的主要核团。兴奋ＤＭＨ、ＶＭＨ所致的心血管效应主要由胞体兴奋诱发,而电刺激ＬＨＡ所致的升压反应主要为兴奋过路纤维引起,该区胞体兴奋主要导致降压反应。     

大鼠延髓外周橄榄腹外侧核在中枢化学感受中的作用

本工作采用微量注射、电损毁、电刺激和微电泳的方法,探讨了大鼠延髓外周橄榄腹外侧核（ＬＶＰＯ）的否真正参与中枢化学感受功能。实验在３８只雄性ＳＤ大鼠上进行。结果表明：（１）微量注射酸化人工脑脊液于ＬＶＰＯ可引起隔神经放电活动明显加强。（２）微电泳给予Ｈ＾＋对ＬＶＰＯ的自发放电单位主要引起兴奋反应,微电泳给予Ｈ＾＋引起兴奋反应的部分单位也可被腹外侧表面微量注射酸化人工ＣＳＦ所兴奋。（３）损毁ＬＶＰＯ后     

电刺激兔肾脏传入神经对血压,心率及加压素释放的影响

本工作以兔为实验对象,观察电刺激肾脏传入神经（ＡＲＮ）对血压、心率、颈交感神经放电、以及加压素（ＡＶＰ）合成和释放的影响,并对ＡＲＮ进入中枢的通路作了观察。结果显示,电刺激ＡＲＮ可以引起血压下降、心率减慢、颈交感神经放电抑制等反应,ＡＲＮ的兴奋还可使下丘脑的视上核、室旁核中的ＡＶＰ含量增加,垂体中ＡＶＰ含量下降,血浆ＡＶＰ水平升高。硝普钠的降压实验和静脉注射ＡＶＰ受体阻断剂ＡＶＰａ的实验均证实了Ａ     

下丘脑室旁核注射神经降压素对大鼠胃酸分泌的影响及机制探讨

本实验用乌拉坦麻醉的大鼠,探讨了下丘脑室旁核（ＰＶＮ）注射神经降压素（ＮＴ）对胃酸分泌的影响及其机制。结果表明,ＰＶＮ注射微量ＮＴ后,胃酸排出量呈剂量依赖性减少,此效应可被侧脑室内预先注射酚妥拉明所阻断,但不能被螺哌啶酮阻断、双侧颈迷走神经切断后,ＰＶＮ注射ＮＴ对胃酸排出量无明显影响。这提示,ＰＶＮ注射ＮＴ对大鼠胃酸分泌的抑制作用,可能与该处α－受体的激活有关,并通过迷走神经所中介。     

孤束核参与刺激下丘脑室旁核的镇痛作用

本实验用电刺激鼠尾-嘶叫法测痛,观察电刺激下丘脑室旁核的镇痛效应,并采用核团损毁和核团内微量注射药物等方法分析其镇痛通路。实验结果如下:(1)电刺激下丘脑室旁核能产生明显的镇痛效应。同时,放射免疫测定发现脑干加压素含量升高。(2)损毁孤束核能取消刺激下丘脑室旁核的镇痛效应,但对基础痛阈无影响。(3)孤束核内微量注射加压素拮抗剂[d(CH_2)_5 TYr(Me)-AVP]60ng/0.6μl 和加压素抗血清0.6μl 都可明显对抗刺激下丘脑室旁核的镇痛效应。(4)直接在孤束核内微量注射加压素60ng/0.6μl,能模拟刺激下丘脑室旁核的镇痛效应。实验结果表明:电刺激下丘脑室旁核能产生镇痛效应,其机理之一可能是兴奋了下丘脑室旁核中加压素能神经元胞体,后者通过下行投射纤维在孤束核中释放加压素,影响孤束核神经元的活动,从而产生镇痛。     

Peroxynitrite scavenging by ferrous truncated hemoglobin GlbO from Mycobacterium leprae

Mycobacterium leprae GlbO has been proposed to represent merging of both O(2) uptake/transport and scavenging of nitrogen reactive species. Peroxynitrite reacts with M. leprae GlbO(II)-NO leading to GlbO(III) via the GlbO(III)-NO species. The value of the second order rate constant for GlbO(III)-NO formation is >1x10(8)M(-1)s(-1) in the absence and presence of CO(2) (1.2x10(-3)M). The CO(2)-independent value of the first order rate constant for GlbO(III)-NO denitrosylation is (2.5+/-0.4)x10(1)s(-1). Furthermore, peroxynitrite reacts with GlbO(II)-O(2) leading to GlbO(III) via the GlbO(IV)O species. Values of the second order rate constant for GlbO(IV)O formation are (4.8+/-0.5)x10(4) and (6.3+/-0.7)x10(5)M(-1)s(-1) in the absence and presence of CO(2) (=1.2x10(-3)M), respectively. The value of the second order rate constant for the peroxynitrite-mediated GlbO(IV)O reduction (= (1.5+/-0.2)x10(4)M(-1)s(-1)) is CO(2)-independent. These data argue for a role of GlbO in the defense of M. leprae against nitrosative stress.     

13C-enrichment at carbons 8 and 2 of uric acid after 13C-labeled folate dose in man

To evaluate folate-dependent carbon incorporation into the purine ring, we measured (13)C-enrichment independently at C(2) and C(8) of urinary uric acid (the final catabolite of purines) in a healthy male after an independent oral dose of [6RS]-5-[(13)C]-formyltetrahydrofolate ([6RS]-5-H(13)CO-H(4)folate) or 10-H(13)CO-7,8-dihydrofolate (10-H(13)CO-H(2)folate). The C(2) position was (13)C-enriched more than C(8) after [6RS]-5-H(13)CO-H(4)folate, and C(2) was exclusively enriched after 10-H(13)CO-H(2)folate. The enrichment of C(2) was greater from [6RS]-5-H(13)CO-H(4)folate than 10-H(13)CO-H(2)folate using equimolar bioactive doses. Our data suggest that formyl C of [6RS]-10-H(13)CO-H(4)folate was not equally utilized by glycinamide ribotide transformylase (enriches C(8)) and aminoimidazolecarboxamide ribotide (AICAR) transformylase (enriches C(2)), and the formyl C of 10-H(13)CO-H(2)folate was exclusively used by AICAR transformylase. 10-HCO-H(2)folate may function in vivo as the predominant substrate for AICAR transformylase in humans.     

Enantioselective recognition of ammonium perchlorate salts by optically active monoaza-15-crown-5 ethers

Chiral monoaza-15-crown-5 ethers (1, 2) were prepared from (R)-(-)-2-amino-1-butanol in high yield. The chiral monoaza-15-crown-5 ethers were purified directly as NaClO(4) complexes. Molecular recognition by these chiral monoaza-crown ethers of (R)- and (S)-PhEtHClO(4) and (R)- and (S)-NapEtHClO(4) as characterized by UV-vis spectroscopy. The order of enantiomeric selectivity is (R)- > (S)- PhEtHClO(4) and (S)- > (R)-NapEtHClO(4) for 1. In the case of 2 it was (R)- > (S)-PhEtHClO(4) and (R)- > (S)- NapEtHClO(4). The cavity of macrocycle and steric hindrance of the benzene units appears to play an important role in recognition.     

Evidence that the tertiary structure of 20(S)-ginsenoside Rg(3) with tight hydrophobic packing near the chiral center is important for Na(+) channel regulation

Ginsenosides are the active ingredients of Panax ginseng. Ginsenoside Rg(3) exists as two stereoisomers of carbon-20: 20-S-protopanaxatriol-3-[O-beta-d-glucopyranosyl (1-->2)-beta-glucopyranoside] (20(S)-Rg(3)) and 20-R-protopanaxatriol-3-[O-beta-d-glucopyranosyl (1-->2)-beta-glucopyranoside] (20(R)-Rg(3)). Recently, we reported that 20(S)-Rg(3) regulates voltage-dependent Ca(2+) channel activity and several types of ligand-gated ion channels, whereas 20(R)-Rg(3) does not have this activity. In this study, we investigated the structure-activity relationship of these two stereoisomers by NMR spectroscopy and by measurement of the current in Xenopus oocytes expressing the mouse cardiac voltage-dependent Na(+) channel (Na(v)1.5). We found that 20(S)-Rg(3) but not 20(R)-Rg(3) inhibited Na(+) channel current in a dose- and voltage-dependent manner. The difference between Rg(3) epimers in voltage-dependent ion channel regulation indicates that the structure of 20(S)-Rg(3) may be geometrically better aligned than that of 20(R)-Rg(3) for interaction with receptor regions in Na(+) channels. The (1)H and (13)C NMR chemical shifts, including all hydroxyl protons of 20(S)-Rg(3) and 20(R)-Rg(3), were completely assigned, and their tertiary structures were determined. 20(S)-Rg(3) has more tight hydrophobic packing near the chiral center than 20(R)-Rg(3). Tertiary structures and activities of 20(S)-Rg(3) and 20(R)-Rg(3) indicate that 20(S)-Rg(3) may have stronger interactions with the receptor region in ion channels than 20(R)-Rg(3). This may result in different stereoselectivity of Rg(3) stereoisomers in the regulation of voltage-dependent Na(+) channel activity. This is the first structural approach to ginsenoside action on ion channel.     

Bradykinin analogs containing the 4-amino-2-benzazepin-3-one scaffold at the C-terminus.

High affinity peptide ligands for the bradykinin (BK) B(2) subtype receptor have been shown to adopt a beta-turn conformation of the C-terminal tetrapeptide (H-Arg(1)-Pro(2)-Pro(3)-Gly(4)-Phe(5)-Ser(6)-Pro(7)-Phe(8)-Arg(9)-OH). We investigated the replacement of the Pro(7)-Phe(8) dipeptide moiety in BK or the D-Tic(7)-Oic(8) subunit in HOE140 (H-D-Arg(0)-Arg(1)-Pro(2)-Hyp(3)-Gly(4)-Thi(5)-Ser(6)-D-Tic(7)-Oic(8)-Arg(9)-OH) by 4-amino-1,2,4,5-tetrahydro-2-benzazepin-3-one templates (Aba). Binding studies to the human B(2) receptor showed a correlation between the affinities of the BK analogs and the propensity of the templates to adopt a beta-turn conformation. The L-spiro-Aba-Gly containing HOE140 analog BK10 has the best affinity, which correlates with the known turn-inducing property of this template. All the compounds did not modify basal inositolphosphate (IP) output in B(2)-expressing CHO cells up to 10 microM concentration. The antagonist properties were confirmed by the guinea pig ileum smooth muscle contractility assay. The new amino-benzazepinone (Aba) substituted BK analogs were found to be surmountable antagonists.     

Crystal-state 3D-structural characterization of novel, Aib-based, turn and helical peptides.

The crystal-state conformations of the hexapeptide amide Pht-(Aib)(6)-NH-C(CH(3))(2)-O-OtBu (7), the hexapeptide Ac-L-aIle-(Aib)(5)-OtBu (6), the pentapeptide Z-(Aib)(3)-L-Glu(OtBu)-Aib-O-(CH(2))(2)-(1)Nap (5), the tetrapeptides Z-(Aib)(2)-L-His(N(tau)-Trt)-Aib-OMe (4 I) and Z-(Aib)(2)-L-Nva-Aib-OtBu (4 II), the tripeptide Pyr-(Aib)(3)-OtBu (3 I), the dipeptide amides Pyr-(Aib)(2)-(4)NH-TEMPO (3 II) and Piv-(Aib)(2)-NH-C(CH(3))(2)-O-OtBu (3 III), and the dipeptides Pht-Aib-betaAc(6)c-OtBu (2 I), Pht-Aib-NH-C(CH(3))(2)-O-OtBu (2 II) and Boc-gGly-mAib-OH (2 III) have been determined by X-ray diffraction analyses. All peptides investigated are characterized by one or more turn/helix forming Aib residues. Except the three short dipeptides, all are folded into C==O...H--N intramolecularly H-bonded 3(10)-helices, or into various types of beta-turns. In the structure of 6, two independent molecules of opposite screw sense were observed in the asymmetric unit, generating diastereomeric 3(10)-helices.     

The first structural study on a cyclic tricoordinate phosphorochloridite and a pentacoordinate phosphorane based on 1,2,3,5-protected myo-inositol--a new conformation of 1,3,2-dioxaphosphorinane ring

Treatment of the phosphoramidite [myo-C(6)H(6)-2-[OC(O)Ph]-1,3,5-(O(3)CH)-4,6-(O(2)P-NH-i-Pr)] with o-chloranil affords the first example of inositol-based pentacoordinate phosphorane [myo-C(6)H(6)-2-[OC(O)Ph]-1,3,5-(O(3)CH)-4,6-(O(2)P-NH-i-Pr)(1,2-O(2)C(6)Cl(4))] (9) (X-ray structure) with a trigonal bipyramidal geometry at phosphorus. The six-membered 1,3,2-dioxaphosphorinane ring with the inositol residue has an unusual boat conformation in 9 which is quite different from that found in unrestrained rings investigated before, but is similar to that of its P(III) chloro precursor [myo-C(6)H(6)-2-[OC(O)Ph]-1,3,5-(O(3)CH)-4,6-(O(2)PCl)] (X-ray structure). Also, a convenient and chromatography-free procedure for the protected myo-inositol derivative [myo-C(6)H(6)-2-[OC(O)Ph]-1,3,5-(O(3)CH)-4,6-(OH)(2)] is reported.     

Hexadecane mineralization and denitrification in two diesel fuel-contaminated soils

The effect of nitrate, ammonium and urea on the mineralization of [(14)C]hexadecane (C(16)H(34)) and on denitrification was evaluated in two soils contaminated with diesel fuel. In soil A, addition of N fertilizers did not stimulate or inhibit background hexadecane mineralization (4.3 mg C(16)H(34) kg(-1) day(-1)). In soil B, only NaNO(3) stimulated hexadecane mineralization (0.91 mg C(16)H(34) kg(-1) day(-1)) compared to soil not supplemented with any nitrogen nutrient (0.17 mg C(16)H(34) kg(-1) day(-1)). Hexadecane mineralization was not stimulated in this soil by NH(4)NO(3) (0.13 mg C(16)H(34) kg(-1) day(-1)), but the addition of NH(4)Cl or urea suppressed hexadecane mineralization (0.015 mg C(16)H(34) kg(-1) day(-1)). Addition of 2 kPa C(2)H(2) did not inhibit the mineralization process in either soil. Denitrification occurred in both soils studied when supplemented with NaNO(3) and NH(4)NO(3), but was not detected with other N sources. Denitrification started after a longer lag in soil A (10 days) than in soil B (4 days). In soil A microcosms supplemented with NaNO(3) or NH(4)NO(3), rates of denitrification were 20.6 and 13.6 mg NO(3)(-) kg(-1) day(-1), respectively, and in soil B, they were 18.5 and 12.5 mg NO(3)(-) kg(-1) day(-1), respectively. We conclude that denitrification may lead to a substantial loss of nitrate, making it unavailable to the mineralizing bacterial population. Nitrous oxide was an important end-product accounting for 30-100% of total denitrification. These results indicate the need for preliminary treatability studies before implementing full-scale treatment processes incorporating commercial fertilizers.     

Manganese inhibition of microbial iron reduction in anaerobic sediments

Potential mechanisms for the lack of Fe(II) accumulation in Mn(IV)‐con‐taining anaerobic sediments were investigated. The addition of Mn(IV) to sediments in which Fe(III) reduction was the terminal electron‐accepting process removed all the pore‐water Fe(II), completely inhibited net Fe(III) reduction, and stimulated Mn(IV) reduction. In a solution buffered at pH 7, Mn(IV) oxidized Fe(II) to amorphic Fe(III) oxide. Mn(IV) naturally present in oxic freshwater sediments also rapidly oxidized Fe(II). A pure culture of a dissimilatory FE(III)‐ and Mn(FV)‐reducing organism isolated from the sediments reduced Fe(III) to Fe(II) in the presence of Mn(IV) when ferrozine was present to trap Fe(II) before Mn(IV) oxidized it. Depth profiles of dissolved iron and manganese reported in previous studies suggest that Fe(II) diffusing up from the zone of Fe(III) reduction is consumed within the Mn(IV)‐reducing zone. These results demonstrate that preferential reduction of Mn(IV) by Fe(III)‐reducing bacteria cannot completely explain the lack of Fe(II) accumulation in anaerobic, Mn(IV)‐containing sedments, and indicate that Mn(IV) oxidation of Fe(II) is the mechanism that ultimately prevents Fe(II) accumulation.